Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Andreas Engert, Prof
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). T...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
HD17 for Intermediate Stage Hodgkin Lymphoma
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof. MD
Update Il y a 4 ans
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokin...
Country
Germany
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Professor
Update Il y a 4 ans
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin ly...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof. MD
Update Il y a 4 ans
EMMA-1 (Erbitux for Multiple Myeloma)
EMMA-1 is an open-label, non-randomized, two-stage phase II study. Patients with refractory multiple myeloma stage II or III or relapsed disease after at least one line of treatment will r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
HD16 for Early Stage Hodgkin Lymphoma
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
The study is designed - to demonstrate efficacy of AFM13 with an optimized treatment schedule - to decide whether AFM13 warrants further investigation in a phase III clinical trial
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma
A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Andreas Engert, Prof
Update Il y a 4 ans
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
The purpose of this trial is to determine 1. Disease stabilization/response rate after six 21-day cycles of ibrutinib 2. Remission status after six, twelve and 20 21-day cycles of ib...
Country
None
organs
None
Specialty
None
Opened trial
More information
1
2
Next